FDA to Phase Out Artificial Dyes: What You Need to Know
CLOSE
Source: Scott Olson / Getty
The Food and Drug Administration (FDA) has announced a major policy shift that will affect some of the most colorful snacks on store shelves.
Popular items like Flamin' Hot Cheetos, Skittles, and Mountain Dew Baja Blast will soon be reformulated as the FDA phases out petroleum-based synthetic dyes.
Here's a breakdown of what you need to know:
The FDA plans to eliminate six synthetic dyes from the U.S. food supply by the end of next year.
This includes: Red 40
Yellow 5
Yellow 6
Blue 1
Blue 2
Green 2
Red Dye 3, previously given a longer timeline, is now also expected to be phased out by the end of 2026.
This policy directly affects products that rely on vibrant synthetic colors, including: Flamin' Hot Cheetos
Skittles
Trix Cereal
Mountain Dew Baja Blast
Froot Loops
And many more from brands like PepsiCo, General Mills, Mars, and WK Kellogg.
The FDA recommends that food manufacturers switch to natural coloring options, such as: Watermelon juice
Beet juice
Carrot juice
These alternatives, while often more expensive, are considered safer for long-term health.
FDA Commissioner Marty Makary cited growing evidence linking artificial dyes to hyperactivity in children and other health concerns.
The move follows years of pressure from health advocates and consumer groups.
Though there isn't a strict ban in place, the FDA and food industry have an understanding.
The agency plans to enforce a national timeline and is exploring all available tools to ensure compliance.
U.S. Health Secretary Robert F. Kennedy Jr. is leading the charge, claiming food and drug industry corruption has made Americans less healthy.
He aims to prioritize nutrition over pharmaceuticals.
In past years, companies like Kraft Heinz reformulated products like mac and cheese to use natural dyes.
Others, like General Mills, temporarily switched but reverted due to poor consumer response.
Companies that help food brands reformulate recipes are now in high demand. McCormick has reported an uptick in activity as more manufacturers look to replace synthetic colors and reduce sodium.
While natural colors are generally more costly to produce, Makary claims this shift shouldn't significantly impact consumer prices, pointing to other countries where similar changes have been implemented successfully. Spring 2025 : FDA begins revoking authorization of synthetic dyes
: FDA begins revoking authorization of synthetic dyes End of 2025 : Red Dye 3 phased out
: Red Dye 3 phased out End of 2026 : Remaining six dyes removed from market
: Remaining six dyes removed from market Ongoing: Approval and rollout of natural dye alternatives
SEE ALSO
FDA to Phase Out Artificial Dyes: What You Need to Know was originally published on b1057.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 hours ago
- Newsweek
Bagel Recall Update As FDA Issues Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of bagels and pastries due to possible undeclared allergens has been issued the second-highest risk warning by the U.S. Food and Drug Administration. The Bonami Baking Company, Inc., based in California, issued a voluntary recall on July 24 for various bagel, bun and croissant products due potential undeclared milk, wheat, eggs, and soy. The FDA later issued a Class II risk classification for the recall on August 13. Newsweek contacted the Bonami Baking Company, Inc. for comment by email outside of regular working hours. Stock image. The Bonami Baking Company, Inc. issued a voluntary recall on July 24 for various bagel, bun and croissant products due potential undeclared allergens. Stock image. The Bonami Baking Company, Inc. issued a voluntary recall on July 24 for various bagel, bun and croissant products due potential undeclared allergens. Francis Chung/POLITICO/AP Why It Matters A Class II risk classification (one of three) refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA. Milk, wheat, eggs and soy are four of the nine major food allergens. The others are fish, crustacean shellfish, tree nuts, peanuts and sesame. Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems. What To Know The products impacted by the recall are the following: Whole Grain Par Baked Jalapeno Cheddar Bagel - 192 cases (72 pieces/case) - undeclared milk Cheddar Bagel - 6,156 pieces - undeclared milk and wheat Chocolate Croissants - 21,096 pieces - undeclared wheat, milk, and soy Whole Wheat Chocolate Croissants - 351 cases (144 pieces/case) - undeclared milk and soy Wheat Hamburger Buns - 61,862 packages (12 dozen/package) - undeclared milk and/or eggs The products have use-by dates between 7/20/2025 and 7/20/2026. They were distributed to retail locations in California. As of August 13, there had been no reports of illnesses in connection to the consumption of the recalled products. What People Are Saying The FDA, on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food." The Mayo Clinic, on its website: "Milk allergy is an atypical immune system response to milk and products containing milk. It's one of the most common food allergies in children. Cow's milk is the usual cause of milk allergy, but milk from sheep, goats, buffalo and other mammals also can cause a reaction. "An allergic reaction usually occurs soon after you or your child consumes milk. Signs and symptoms of milk allergy range from mild to severe and can include wheezing, vomiting, hives and digestive problems. Milk allergy can also cause anaphylaxis — a severe, life-threatening reaction." Dr. Sebastian Lighvani, director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods." What Happens Next The recalls are listed as ongoing, according to the FDA. Consumers who have allergies or sensitives to milk, wheat, eggs and soy should not consume the recalled products.
Yahoo
3 hours ago
- Yahoo
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "BrainStorm remains focused on executing our clinical development plan for NurOwn®. We reached an important milestone in Q2 with FDA clearance to initiate our Phase 3b trial, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We are also advancing key operational activities, including discussions with clinical sites as well as ongoing engagement with our selected CDMO partners to ensure readiness for clinical drug supply. We are encouraged by the ongoing interest and support from clinicians and the ALS community, and we remain confident that, if approved, NurOwn has the potential to make a meaningful difference for patients and their families." Mr. Lebovits continued, "We support the FDA's consideration of the Citizen Petition, which may provide a fresh opportunity for an objective evaluation of the scientific evidence. We continue to stand behind the integrity and rigor of our data and will continue to engage with clinicians and the ALS community." Recent Highlights NurOwn (MSC-NTF) for ALS FDA has cleared the company to initiate the Phase 3b clinical trial of NurOwn® The Phase 3b trial, known as ENDURANCE, is expected to enroll approximately 200 participants at leading academic medical centers and will consist of a 24-week randomized, double-blind, placebo-controlled phase, followed by a 24-week open-label extension in which all participants will receive NurOwn. The primary endpoint is the change from baseline to week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R). Successful completion of the double blind portion of the study (Part A) is expected to generate the clinical data needed to support a new BLA submission. Details of the trial, including a list of anticipated participating clinical sites, are available on ID NCT06973629. A Citizens Petition submitted to the FDA by ALS Community requesting a new review of the NurOwn data The company acknowledges that the FDA's consideration of the petition provides a new opportunity to reaffirm NurOwn's potential as a therapy for ALS. BrainStorm was not involved in drafting or submitting this petition or its contents. New survival data from NurOwn Expanded Access Program show that 100% of participants (10/10) in the EAP survived more than 5 years from the onset of ALS symptoms, compared to published estimates indicating that approximately 10% of individuals with ALS would survive beyond 5 years. The single death in the cohort occurred following elective euthanasia. The median survival observed in the EAP cohort was 6.8 years (range: 6 to 7 years) from symptom onset. Although the EAP cohort included participants earlier in their disease course, these results are encouraging and support further study. Manufacturing Partnership with Minaris BrainStorm has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn for the upcoming Phase 3b clinical trial. NurOwn® data selected as Breakthrough Science for Presentation at ISCT 2025 Meeting The new pharmacogenomic data were delivered in an oral presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting in May 2025, in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn. The presentation was featured in the ISCT public announcement regarding the meeting, which indicated that the data were "carefully reviewed and selected by the ISCT 2025 Planning Faculty, to explore the latest breakthroughs in the clinical translation of Mesenchymal Stem/Stromal Cells and how they will shape the future of cell therapies." Financial Results for the Second quarter Ended June 30, 2025 Cash, cash equivalents, and restricted cash were approximately $1.03 million as of June 30, 2025. Research and development expenditures, net, for the quarter ended June 30, 2025 were $1.1 million, compared to $0.9 million for the quarter ended June 30, 2024. General and administrative expenses for the quarter ended June 30, 2025 were approximately $1.4 million, compared to approximately $2.1 million for the quarter ended June 30, 2024. Net loss for the quarter ended June 30, 2025, was approximately $2.9 million, as compared to a net loss of approximately $2.5.4 million for the quarter ended June 30, 2024. Net loss per share for the three months ended June 30, 2025, and 2024 was $0.34 and $0.60, respectively. Conference Call and Webcast Participant Numbers: Toll Free 877-545-0320 International 973-528-0002 Participant Access Code 601260 Webcast The replay of the conference call can be accessed by dialing the numbers below and will be available until August 28. Replay Numbers: Toll Free 877-481-4010 International 919-882-2331 Reply Passcode 52831 About NurOwn® The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit Notice Regarding Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. CONTACTS Investors:Michael WoodPhone: +1 646-597-6983mwood@ Media: Uri Yablonka, Chief Business OfficerPhone: +1 917-284-2911uri@ CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (Except share data) June 30,December 31, 20252024 UnauditedAudited U.S. $ in thousands ASSETSCurrent Assets: Cash and cash equivalents$ 824$ 187 Other accounts receivable 106 63 Prepaid expenses and other current assets 585 135 Total current assets$ 1,515$ 385Long-Term Assets: Prepaid expenses and other long-term assets $ 24$ 22 Restricted Cash 201 184 Operating lease right of use asset (Note 3) 495 807 Property and Equipment, Net 331 434 Total Long-Term Assets$ 1,051$ 1,447Total assets$ 2,566$ 1,832LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current Liabilities: Accounts payables$ 5,997$ 6,080 Accrued expenses 367 619 Short-term loans (Note 7) 101 300 Operating lease liability (Note 3) 381 549 Employees related liability 1,682 1,430 Total current liabilities$ 8,528$ 8,978Long-Term Liabilities: Operating lease liability (Note 3) 95 171 Warrants liability (Note 4) - 447 Total long-term liabilities$ 95$ 618Total liabilities$ 8,623$ 9,596Stockholders' Deficit: Stock capital: (Note 5) 16 14 Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at June 30, 2025 and at December 31, 2024 respectively; Issued and outstanding: 10,120,109 and 6,141,762 shares at June 30, 2025 and December 31, 2024 respectively Additional paid-in-capital 226,446 218,974 Treasury stocks (116) (116) Accumulated deficit (232,403) (226,636) Total stockholders' deficit$ (6,057)$ (7,764)Total liabilities and stockholders' deficit$ 2,566$ 1,832 BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) U.S. dollars in thousands (Except share data) Six months ended Three months ended June 30, June 30, 2025202420252024 UnauditedUnaudited Operating expenses:Research anddevelopment, net$ 2,424$ 1,883$ 1,120$ 922 General and administrative 3,238 3,573 1,453 2,060Operating loss (5,662) (5,456) (2,573) (2,982)Financial income (expense), net (284) 43 (330) 30Gain (loss) on change in fair value of Warrants liability (Note 4) 179 529 - (411)Net loss$ (5,767)$ (5,942)$ (2,903)$ (2,541)Basic and diluted net lossper share from continuing operations$ (0.77)$ (1.35)$ (0.34)$ (0.60)Weighted average numberof shares outstanding usedin computing basic and diluted net loss per share 7,487,495 4,531,801 8,620,400 4,747,699 Logo - View original content to download multimedia: SOURCE BrainStorm Cell Therapeutics Inc.
Boston Globe
4 hours ago
- Boston Globe
Whoop there it is: FDA wants to regulate wearable firm's blood pressure tool
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up But in a response sent Aug. 4, Whoop rejected the FDA's assessment, saying the software didn't meet the definition of a medical device and the company would continue to offer the feature to users. The company, which shared the letter with The Boston Globe, also argued the move went against the goals of the Trump administration. Advertisement 'Seeking to regulate the feature as a medical device also runs counter to the stated policy of the Secretary of the Department of Health and Human Services, Robert F. Kennedy Jr., of 'clearing away regulatory barriers so innovation can thrive,'' Whoop said in the letter. Advertisement Whoop's refusal to comply with the FDA's request is uncommon, legal experts said. The FDA, which oversees the safety of medical devices and pharmaceuticals, is usually the ultimate decider of what comes under its jurisdiction and which devices can be sold to help people manage or treat health conditions. Chris Robertson, a Boston University law professor who teaches FDA law, said any communication from the FDA to a company is typically enough to make the company get in line with federal standards. 'You're playing with fire here,' Robertson said. 'That means that Whoop is taking a real calculated gamble.' Wearable technology sits in a grey area when it comes to regulation. The wearables market, estimated by one market intelligence group to be worth $84 billion in 2024, is rapidly expanding, and companies are racing to add new features that give users unique health measurements. Related : Smart wristbands, watches and rings that assess heart rates don't have to get cleared as medical devices. But Whoop competitors, such as Apple and Fitbit, have sought FDA approval for certain software tools in recent years. The crux of Whoop's argument rests on the 21st Century Cures Act, a 2016 law that exempts wellness software features from the definition of a medical device, so long as those features aren't related to the diagnosis, prevention, or treatment of a disease. Blood Pressure Insights, Whoop said, is only intended to be used as a way to gauge a person's performance, quality of sleep, and stress levels . The FDA, however, has rejected Whoop's characterization of the blood pressure tool. In its letter, the agency said the product qualifies as a medical device because its measurements are 'inherently associated with the diagnosis of a disease or condition,' such as hypertension, or high blood pressure. Advertisement Whoop has registered one of its products with the FDA, securing medical device approval for its Heart Screener tool. That tool measures the heart's electrical activity to alert users to potentially abnormal heart rates and atrial fibrillation, a common type of abnormal heart rhythm. The FDA said it doesn't comment on 'ongoing investigations, compliance matters or enforcement activities except with the company involved.' Related : The confrontation is reminiscent of the clash more than a decade ago between the FDA and the personal genomics platform 23andMe, said health law expert Frances Miller, who also teaches at Boston University. The FDA and 23andMe went back and forth on whether the company's health test — which the company claimed could tell customers their risk of conditions like gallstones, heart disease, or arthritis — constituted a medical device. In 2013, the FDA sent a warning letter to 23andMe much like the one it sent Whoop, and 23andMe ultimately capitulated. But the landscape looks different today, Miller said. The FDA has experienced significant cuts under President Trump, and federal agencies as a whole have lost power. In addition, Kennedy has publicly stated his vision that 'every American is wearing a wearable within four years.' Whether Whoop will win its fight against regulation is unclear, Miller said. 'I could have given you a very confident answer a year and a half ago,' Miller said. 'Not now. They're pushing the envelope.' Marin Wolf can be reached at
